Krsnaa Diagnostics, a small-cap company in the healthcare services industry, has reported a solid financial performance for the second quarter of FY25. The company’s net sales reached ₹186.34 crore, marking its highest sales figure in the last five quarters. This consistent growth highlights the positive near-term outlook for Krsnaa Diagnostics.
The company also saw a 50.2% growth in profit before tax (PBT) less other income, reaching ₹20.81 crore, compared to the average PBT of the previous four quarters. Additionally, the operating profit (PBDIT) surged to ₹49.40 crore, the highest in five quarters, reflecting improved efficiency with an operating profit margin of 26.51%.
Krsnaa Diagnostics recorded its highest PBT of ₹20.81 crore and PAT of ₹19.60 crore in the last five quarters. With a 30.4% growth in PAT compared to the previous four quarters, the company is showcasing strong profitability and increasing earnings for shareholders.
As of 9:17 am the shares were trading 5.75% higher at ₹829.20
As Krsnaa Diagnostics continues its upward trend in financial performance, it presents a potential investment opportunity in the healthcare sector, driven by strong sales growth and improving operational efficiency.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
